New drugs for the treatment of chronic, non-cancerous pain are approved by the FDA July 26, 2016 Source: WuXi PharmaTech Recently, the US FDA approved a new product, RELISTOR (methylnaltrexonebromide, methylnaltrexone bromide), for the treatment of adult patients suffering from chronic non-cancerous pain due to constipation (OIC) caused by the use of opioids. Recently, Valeant Pharmaceuticals International and its partner Progenics Pharmaceuticals announced that the US FDA has approved its product RELISTOR (methylnaltrexonebromide, methyl naltrexone) oral tablets for the treatment of constipation (OIC) caused by the use of opioids. Patients, they suffer from chronic non-cancerous pain. Valeant expects to begin selling RELISTOR in the US in the third quarter of 2016. According to statistics, more than 1.5 million patients in the United States receive analgesic treatment each year because of advanced diseases such as cancer, advanced cardiopulmonary disease or AIDS. Many of these patients often use opioids to relieve pain. Opioids exert specific analgesic effects by binding to opioid receptors in the central nervous system of the brain and spinal cord. However, studies have also found that opioids can interact with opioid receptors in the peripheral nervous system (such as the gastrointestinal tract), triggering a series of adverse reactions, of which the most obvious symptoms are. This type of constipation is a serious side effect, and current treatments such as laxatives or stool softeners are not sufficient. RELISTOR is an opioid receptor antagonist that selectively competes with opioids that bind to opioid receptors outside the central nervous system, including the gastrointestinal tract. Thus, RELISTOR can block the adverse effects caused by the combination of opioids and receptors, and it can also effectively promote colonic peristalsis and reduce constipation. Due to its unique chemical structure, RELISTOR does not pass the blood-brain barrier and does not affect the analgesic effect of opioids on the central nervous system. Based on a randomized, double-blind, placebo-controlled phase 3 clinical trial, the US FDA approved RELISTOR oral tablets (450 mg once daily) for adult treatment of chronic non-cancerous pain. The treatment group with oral 450 mg drug reached the primary clinical endpoint compared with placebo treatment and showed a statistically significant improvement in defecation behavior. Previously, RELISTOR subcutaneous injections (12 mg and 8 mg) were approved in 2008 in many parts of the world. Mr. Joseph C. Papa, CEO of Valeant, said: "Opiate-induced constipation represents a long-lasting potential side effect of the use of opioids in the treatment of millions of patients with chronic pain. We believe in oral RELISTOR It is a new alternative treatment for OIC, and we look forward to introducing a more convenient and simple oral preparation as soon as possible.
The plastic beaded seals have a beaded tail. When the tail goes through the locking hole, the locking mechanism provides a strength to stop its entrance.
The plastic beaded seals are adjustable indicative plastic security seal ideal for sealing varying sized items.
The applications for beaded seals include: Trailer Doors, Bulk Tankers, Railcars, Tote Boxes, Fibre Drums, Storage Cabinets. The material is high Density Polyethylene and Acetal. The marking can be Hot Stamped Printing or laser engraving.
Plastic Beaded Seals,Plastic Beaded Seal,pull tight seals,Plastic Locking Mechanism Seals Wenzhou Haoshi Light Industrial Products Co., LTD , https://www.economicseals.com